Editorial
A novel indication to treat distinct types of tumors with PD-1 blockade based on mismatch-repair deficiency
Abstract
Le et al. conducted a prospective study (Clinical-Trials.gov number, NCT01876511) to evaluate effects of programmed death-1 (PD-1) blockade (pembrolizumab) therapy in different kinds of tumors with mismatch repair-deficient (1).
